Sitemap Contact Privacy Statement Imprint

Microphysiological tissue models

The number of successful drug development projects has stagnated for decades, despite major breakthroughs in chemistry, molecular biology and genetics. Unreliable target identification and poor translatability of preclinical results have been identified as major causes of failure. To improve predictions of clinical efficacy and safety, interest has shifted from conventional 2D cultures to organotypic and microphysiological culture methods in which human cells can retain physiologically and functionally relevant phenotypes for extended periods of time. The Lauschke lab integrates 3D cell culture systems of primary human cells, microfluidics and comprehensive molecular profiling technologies to discover mechanisms underlying inflammatory conditions (NASH), infectious diseases (COVID-19 and hemorrhagic fevers) and complex metabolic diseases (type 2 diabetes), and to develop novel therapeutic strategies by interfacing tissue engineering with high-throughput drug development. In addition, the group uses population-scale genomic data and machine learning to map the ethnogeographic variability in genes involved in drug absorption, distribution, metabolism and excretion, as well as drug targets with a specific focus on the contribution that rare genetic variations play in drug response and toxicity and how this information can improve personalized medicine and precision public health.
Major Projects
  • Development of microphysiological patient-derived tissue models of liver, pancreas, skeletal muscle and adipose tissue
  • Development of hepatic disease models for drug discovery
  • Micro- and nanoengineering of microfluidic devices
  • Integrated microfluidic models for studies of complex diseases
  • High-throughput drug development
  • Development of JAK inhibitors for COVID-19
  • Evaluation of the importance of rare genetic variants on hepatic metabolism and drug response
Prof. Dr. Volker Lauschke

phone: ++49-711-8101 2060

Selected References

Highlighted References

Major Networks
  • Board member of the Swedish Society of Medicine (Section of Pharmacology)
  • Member of the IUPHAR (International Union of Basic & Clinical Pharmacology) Young Investigator Committee
  • Member of the Swedish Strategic Research Program in Diabetes
  • Member of the Pharmacogene Variation Consortium (PharmVar)
  • Member of the Management Committee of the COST Action “Prospective European Drug-Induced Liver Injury (DILI) Network”
  • Member of the International Network Medicine Consortium (INMC) Steering Group
Funding
  • ERC
  • Vetenskapsrådet
  • the Knut and Alice Wallenberg Foundation
  • the IMI2 project EUbOPEN
  • the Organ-On-A-Chip Technologies Network
  • the Ruth and Richard Julins Foundation for Gastroenterology
  • the Swedish Strategic Research Programs in Diabetes (SRP Diabetes)
  • Stem Cells and Regenerative Medicine (StratRegen)
  • Furthermore, we acknowledge support from Merck KGaA and Eli Lilly and Company

Curriculum Vitae Volker Lauschke, PhD

Affiliation
Deputy Head at the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP), Stuttgart, Germany
Research Group Leader Microphysiological Tissue Models

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology
Auerbachstr. 112
D-70376 Stuttgart Germany
phone: ++49-711-8101 2060
fax: ++49-711-859295
email: volker.lauschke@ikp-stuttgart.de
Education and Professional Career
 Current Academic Positions
 Since 2021 Deputy Head of the Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP), Stuttgart, Germany
 Since 2018 Director of the Biofabrication and Tissue Engineering facility at Karolinska Institutet
 Since 2017 Associate Professor and Group Leader in Personalized Medicine and Drug Development, Karolinska Institutet, Stockholm, Sweden (Venia legendi (Docentur) in Pharmacology since 2018).
 Current Corporate Positions
 Since 2021 Co-founder and CSO of PersoMedix AB
 Since 2016 Co-founder and CEO of HepaPredict AB
 Professional Experience
 2014 – 2016 Postdoctoral Research Associate and MarieCurie Fellow;
Karolinska Institutet, Stockholm, Sweden, Supervisor: Prof. Magnus Ingelman-Sundberg
 2013 – 2014 Bridging Postdoctoral Research Associate. Same as below.
 2009 – 2013

Dr. rer. nat. (PhD) Grade 1.0;
Graduation Summa cum Laude (best possible grade)
European Molecular Biology Laboratory (EMBL) and the joint faculty of Science and Mathematics of the Ruperto-Carola University, Heidelberg, Supervisor: Dr. Alexander Aulehla

 University Studies
 2007 – 2009 Master of Science (M.Sc.) in Molecular Biosciences;
Grade: 1.0, Ruperto-Carola University, Heidelberg, Germany
 2004 – 2007 Bachelor of Science (B.Sc.) in Molecular and Cellular Biology;
Grade: 1.6, Ruperto-Carola University, Heidelberg, Germany and University of Bergen, Norway
 Additional Academic Qualifications
 2016 – 2018 Master of Science (M.Sc.) in Business Administration and Economics;
Majors: International Management and Operations Research, University of Hagen, Germany
 2012 – 2016 Bachelor of Science (B.Sc.) in Business Administration and Economics;
Majors: Audit, Taxation and Business Analysis, University of Hagen, Germany 
Fellowships, Prizes and Awards
  • 2020 AAPS (American Association of Pharmaceutical Scientists) High Impact Award 2020
  • 2017 Lennart Philipson Prize
  • 2014 Marie Curie Fellowship
  • 2009 EMBL International PhD Program Graduate Fellowship
  • 2009 Top Master of Science (M.Sc.) Award
  • 2006 Erasmus Fellowship (Ecotoxicology at the University of Bergen, Norway)
  • 2002 Fördern, Fordern, Forschen Award
Grants and Funding
  • 2020 Bioprinting Infrastructure Grant
  • Knut and Alice Wallenberg Foundation COVID19 Grant
  • Ruth and Richard Julins Foundation for Gastroenterology
  • StratRegen Project Grant
  • International Network Medicine Consortium (INMC) Seed Grant
  • Swedish Research Foundation (VR) 3R Grant
  • Organ-On-A-Chip Technologies Network Grant
  • ERC Synergy grant SPHERES
  • IMI2 EUbOPEN
  • Horizon 2020 UPGx
  • Rolf Luft Grant for Diabetes Research
  • Swedish Research Foundation (VR) Starting Grant

In addition, we receive generous funding from Karolinska Institutet, the Robert Bosch Foundation for Medical Research, Merck KGaA and Eli Lilly and Company.

Teaching Portfolio
Teaching activities include seminars and practical courses in local anaesthetics, cardiovascular pharmacology, pharmacokinetics and receptor pharmacology for biomedical, medical and dentistry students.
Commissions of Trust and Memberships in Scientific Societies
  • Since 2021: TATA Fellow of the Institute of Liver and Biliary Sciences (ILBS), New Delhi, India
  • Since 2021: Co-founder and CSO of PersoMedix AB
  • Since 2019: International Union of Basic & Clinical Pharmacology Young Investigator Committee
  • Since 2019: Board member of the Swedish Society of Medicine (Section of Pharmacology)
  • Since 2019: Member of the Management Committee of the COST Action “Prospective European Drug-Induced Liver Injury (DILI) Network”
  • Since 2019: Member of the International Network Medicine Consortium (INMC) Steering Group
Editorial Board Member
  • Human Genomics
  • Drug Metabolism Reviews
  • Pharmacogenomics Research and Personalized Medicine
  • Precision Cancer Medicine
  • Computational & Structural Biotechnology Journal
  • The Pharmacogenomics Journal
  • Current Research in Pharmacology and Drug Discovery
  • + 3 more
Reviewer for National Agencies
  • Welcome Trust (2018)
  • Health Canada & GenomeBC Canada (2017, 2018, 2019)
  • Hong Kong Innovation and Technology Commission (2019)
  • Swiss Science Foundation (2020)
  • Dutch Research Foundation (2020)
  • French Research Council (2021)
  • Israeli Science Foundation (2021)
  • German Science Foundation – Network of University Medicine (2021)
  • Dutch Research Council (NWO; 2021)